To test the potential therapeutic efficacy of PRMT5 inhibition in an intracranial xenograft model of GBM, we transplanted 20,000 GSCs (G411) into NSG mice (n = 24) and initiated treatment 1 week after intracranial injection. Here, PRMT5 is linked to glioblastoma.